Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs Standard-dose Capecitabine in Elderly CRC
NCT02316535Phase 3Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02316535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316535.